| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1877 | 2020 |
| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of oncology 32 (6), 787-800, 2021 | 304 | 2021 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 183 | 2021 |
| Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma VS Koshkin, PC Barata, T Zhang, DJ George, MB Atkins, WJ Kelly, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 175 | 2018 |
| Caspase-mediated cell death predominates following engraftment of neural progenitor cells into traumatically injured rat brain A Bakshi, CA Keck, VS Koshkin, DG LeBold, R Siman, EY Snyder, ... Brain research 1065 (1-2), 8-19, 2005 | 123 | 2005 |
| Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin CE Chu, M Sjöström, EA Egusa, EA Gibb, ML Badura, J Zhu, VS Koshkin, ... Clinical Cancer Research 27 (18), 5123-5130, 2021 | 95 | 2021 |
| Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance PC Barata, VS Koshkin, P Funchain, D Sohal, A Pritchard, S Klek, ... Annals of Oncology 28 (10), 2458-2463, 2017 | 79 | 2017 |
| Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook D Gopalakrishnan, VS Koshkin, MC Ornstein, A Papatsoris, P Grivas Therapeutics and clinical risk management, 1019-1040, 2018 | 69 | 2018 |
| Transcriptomic and protein analysis of small-cell bladder cancer (SCBC) identifies prognostic biomarkers and DLL3 as a relevant therapeutic target VS Koshkin, JA Garcia, J Reynolds, P Elson, C Magi-Galluzzi, ... Clinical Cancer Research 25 (1), 210-221, 2019 | 64 | 2019 |
| Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT# 02844816). PC Black, C Tangen, P Singh, DJ McConkey, S Lucia, WT Lowrance, ... Journal of Clinical Oncology 38 (15_suppl), 5022-5022, 2020 | 60 | 2020 |
| Emerging role of immunotherapy in advanced urothelial carcinoma VS Koshkin, P Grivas Current oncology reports 20, 1-10, 2018 | 55 | 2018 |
| TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells J Chou, K Trepka, M Sjöström, EA Egusa, CE Chu, J Zhu, E Chan, ... European urology oncology 5 (6), 714-718, 2022 | 53 | 2022 |
| HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer M Alyamani, H Emamekhoo, S Park, J Taylor, N Almassi, S Upadhyay, ... The Journal of clinical investigation 128 (8), 3333-3340, 2018 | 51 | 2018 |
| Racial disparities in COVID-19 outcomes among black and white patients with cancer J Fu, SA Reid, B French, C Hennessy, C Hwang, NT Gatson, N Duma, ... JAMA network open 5 (3), e224304-e224304, 2022 | 50 | 2022 |
| A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors AR Khaki, A Li, LN Diamantopoulos, NJ Miller, L Carril-Ajuria, ... European urology oncology 4 (3), 464-472, 2021 | 48 | 2021 |
| Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study VS Koshkin, N Henderson, M James, D Natesan, D Freeman, A Nizam, ... Cancer 128 (6), 1194-1205, 2022 | 44 | 2022 |
| Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19 AL Schmidt, MD Tucker, Z Bakouny, C Labaki, CY Hsu, Y Shyr, ... JAMA network open 4 (11), e2134330-e2134330, 2021 | 42 | 2021 |
| Systematic review: targeting HER2 in bladder cancer VS Koshkin, P O’Donnell, EY Yu, P Grivas Bladder Cancer 5 (1), 1-12, 2019 | 40 | 2019 |
| Health-related quality of life and pain outcomes with [177Lu] Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant … K Fizazi, K Herrmann, BJ Krause, K Rahbar, KN Chi, MJ Morris, O Sartor, ... The Lancet Oncology 24 (6), 597-610, 2023 | 38 | 2023 |
| Interplay of immunosuppression and immunotherapy among patients with cancer and COVID-19 Z Bakouny, C Labaki, P Grover, J Awosika, S Gulati, CY Hsu, ... JAMA oncology 9 (1), 128-134, 2023 | 34 | 2023 |
Pedro BarataAssociate Professor, University Hospitals Seidman Cancer Center, Case Western University在 UHhospitals.org 的电子邮件经过验证
